中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 5
May  2018
Turn off MathJax
Article Contents

Value of preoperative and postoperative carbohydrate antigen 19-9 levels in predicting prognosis and early recurrence in patients with hilar cholangiocarcinoma

DOI: 10.3969/j.issn.1001-5256.2018.05.024
  • Received Date: 2017-11-06
  • Published Date: 2018-05-20
  • Objective To investigate the value of preoperative and postoperative carbohydrate antigen 19-9 ( CA19-9) levels in predicting the prognosis and early recurrence of patients with hilar cholangiocarcinoma ( HCCA) . Methods A total of 80 patients with HCCA who underwent radical resection in The Second Affiliated Hospital of Shaanxi University of Chinese Medicine from January 2001 to December2013 were enrolled. According to their medical records and examination results, the clinical data including age and sex were recorded. Electrochemical luminescence was used to measure the serum level of CA19-9. The cut-off points of preoperative and postoperative CA19-9 levels in predicting the survival rate of HCCA patients were divided into ≤100 U/ml and > 100 U/ml groups, ≤150 U/ml and > 150 U/ml groups, ≤200 U/ml and > 200 U/ml groups, and ≤400 U/ml and > 400 U/ml groups. The Kaplan-Meier method was used to compare the survival rate between CA19-9 ≤150 U/ml group and CA19-9 > 150 U/ml group, as well as between increased CA19-9 group, ≤50% reduction in CA19-9 group, and > 50% reduction in CA19-9 group. Univariate and multivariate non-conditional logistic regression analyses were used to analyze the association of preoperative and postoperative CA19-9 levels with clinical data. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results There was a significant difference in the prediction of survival time of HCCA patients undergoing radical resection between the cut-off points of preoperative CA19-9 of 100, 150, 200, and 400 U/ml ( t = 2. 85, 3. 66, 2. 84, and 2. 55, P < 0. 05) , as well as between the cut-off points of postoperative CA19-9 of 100, 150, 200, and 400 U/ml ( t = 3. 06, 4. 55, 3. 08, and 5. 15, P < 0. 05) . The Kaplan-Meier survival analysis showed that the HCCA patients undergoing radical resection with a preoperative CA19-9 level of ≤150 U/ml had a significantly higher survival rate than those with a preoperative CA19-9 level of > 150 U/ml ( P < 0. 05) ; the HCCA patients undergoing radical resection with a postoperative CA19-9 level of ≤150 U/ml had a significantly higher survival rate than those with a postoperative CA19-9 level of > 150 U/ml ( P < 0. 05) . The HCCA patients who underwent radical resection and had an increase in CA19-9 after surgery had a significantly higher survival rate than those who had a ≤50% or > 50% reduction in CA19-9 after surgery ( both P < 0. 05) .The univariate and multivariate analyses showed that in HCCA patients undergoing radical resection, the preoperative CA19-9 level was associated with lymph node metastasis and early recurrence ( both P < 0. 05) and the postoperative CA19-9 level was associated with early recurrence ( P < 0. 05) . Conclusion Preoperative and postoperative CA19-9 levels can be used to predict survival and early recurrence of patients with resectable HCCA. An increase in CA19-9 level after surgery may cause early recurrence and poor survival outcome in patients with HCCA.

     

  • loading
  • [1]WANG QR, ZHANG Y, MU D, et al.Association between hematobilia and primary disease after therapeutic endoscopic retrograde cholangiopancreatography[J].J Clin Hepatol, 2017, 33 (5) :896-898. (in Chinese) 王群茹, 张勇, 牟东, 等.治疗性经内镜逆行胰胆管造影术后胆道出血与原发疾病的关系[J].临床肝胆病杂志, 2017, 33 (5) :896-898.
    [2]XIANG S, WAN YL, CHEN X.Hilar cholangiocarcinoma:Controversies on the extent of surgical resection aiming at cure[J].Int J Colorectal Dis, 2015, 30 (2) :159-171.
    [3]HU HJ, HUI M, TAN YQ, et al.Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma[J].Springerplus, 2016, 5 (1) :551-559.
    [4]LI M, KAI L, QI X, et al.Percutaneous transhepatic biliary stent implantation for obstructive jaundice of perihilar cholangiocarcinoma:a prospective study on predictors of stent patency and survival in 92 patients[J].J Vasc Interv Radiol, 2016, 27 (7) :1047-1055.
    [5]CUI DP, ZHANG YC, GAO SQ, et al.Value of serum carbohydrate antigens 19-9 and 24-2 in diagnosis of benign and malignant biliary tract diseases[J].J Clin Hepatol, 2016, 32 (7) :1364-1367. (in Chinese) 崔大鹏, 张迎春, 高树全, 等.血清糖链抗原19-9、糖链抗原24-2对良恶性胆道疾病的诊断价值[J].临床肝胆病杂志, 2016, 32 (7) :1364-1367.
    [6]FENG F, TIAN Y, XU G, et al.Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer[J].BMC Cancer, 2017, 17 (1) :737-743.
    [7] Anti-cancer Association of China.Guideline for the diagnosis and therapy of hilar cholangiocarcinoma (2015) [J].Chin J Hepatobiliary Surg, 2015, 21 (8) :505-511. (in Chinese) 中国抗癌协会.肝门部胆管癌规范化诊治专家共识 (2015) [J].中华肝胆外科杂志, 2015, 21 (8) :505-511.
    [8]EBATA T, KOSUGE T, HIRANO S, et al.Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas[J].Br J Surg, 2014, 101 (2) :79-88.
    [9]WANG Y, YANG H, SHEN C, et al.Surgical procedure and long-term survival of hilar cholangiocarcinoma[J].Int J Clin Exp Med, 2015, 8 (1) :1122-1128.
    [10]CAI WK, LIN JJ, HE GH, et al.Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma[J].Int J Clin Exp Pathol, 2014, 7 (11) :7890-7898.
    [11]YIN XY, LIU X, CHEN W, et al.Long-term outcomes and prognostic factors of surgical resection of hilar cholangiocarcinoma[J].Chin J Dig Surg, 2016, 15 (4) :329-333. (in Chinese) 殷晓煜, 刘鑫, 陈伟, 等.肝门部胆管癌手术切除的远期疗效及预后因素分析[J].中华消化外科杂志, 2016, 15 (4) :329-333.
    [12]SUI XL, TANG HH, XIAO GF, et al.Clinical efficacy and prognostic factors analysis of hilar cholangiocarcinoma in 322 patients[J].Chin J Dig Surg, 2017, 16 (4) :391-397. (in Chinese) 隋鑫磊, 汤恢焕, 肖广发, 等.322例肝门部胆管癌的临床疗效及预后因素分析[J].中华消化外科杂志, 2017, 16 (4) :391-397.
    [13]LI L, WANG J, SHANG PZ.Expressions of Annexin A1 and CA19-9 in cholangiocarcinoma and their clinicopathological significance[J].China J Modern Med, 2016, 26 (10) :31-35. (in Chinese) 李辽, 王金, 尚培中.膜联蛋白A1和CA19-9在胆管癌中的表达及其临床意义[J].中国现代医学杂志, 2016, 26 (10) :31-35.
    [14]HU SZ, WANG X, KONG J.Clinical data and differential diagnosis of hilar cholangiocarcinoma and hilar benign diseases[J].Chin J Bases and Clin Gen Surg, 2017, 1 (3) :343-348. (in Chinese) 胡尚志, 王鑫, 孔静.肝门胆管癌与肝门部良性疾病的临床资料比较和鉴别诊断[J].中国普外基础与临床杂志, 2017, 1 (3) :343-348.
    [15]WANG JK, HU HJ, SHRESTHA A, et al.Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?[J].Oncotarget, 2017, 8 (28) :45335-45344.
    [16]LAI JF, XU WN, NOH SH, et al.Effect of World Health Organization (WHO) histological classification on predicting lymph node metastasis and recurrence in early gastric cancer[J].Med Sci Monit, 2016, 22 (5) :3147-3153.
    [17]DEOLIVEIRA ML, CUNNINGHAM SC, CAMERON JL, et al.Cholangiocarcinoma:thirty-one-year experience with 564 patients at a single institution[J].Ann Surg, 2007, 245 (5) :755-762.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (599) PDF downloads(68) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return